–by Vijendra K. Singh, Ph.D., Director of Research, Brain State Technologies, Scottsdale, AZ
More than 50 million people in the United States suffer from autoimmune diseases due to an abnormal immune reaction called autoimmunity. Autoimmunity is a major cause of many chronic diseases. This number, however, does not include several brain diseases and mental illnesses for which brain autoimmunity has been experimentally demonstrated. For example, a huge population with autism spectrum disorders (ASD), Alzheimer’s disease (AD), Tourette’s syndrome (TS) and obsessive-compulsive disorder (OCD) has been found to have autoimmunity to brain. This patient population is never included in epidemiological studies of the autoimmune diseases.
If you have an autoimmune disease, your immune system goes haywire and begins to attack healthy cells, tissues, and organs. However, this must happen in a highly select way. Thus, in certain cases, the immune system will elicit autoimmune response towards the brain or nerve tissue. To that end, a term “NeuroAutoImmunity” (NAI) has recently been used to refer to this autoimmune response that is directed against the brain or nerve tissue. Our immune system and nervous system are connected with each other via the so-called neuro-immune circuitry; and when this circuitry is disrupted, the most common problem manifested is autoimmunity to brain. Then, people commonly show a wide spectrum of neurological and psychiatric health problems.
What causes autoimmune diseases is not well known. The common belief is that they are triggered by environmental factors, in particular viruses; for example, human herpes virus-6 in multiple sclerosis (MS), measles virus in autism spectrum disorders, and herpes simplex virus in Alzheimer’s disease. Virus infection is now known to change the permeability of the blood-brain barrier, which permits the entry of immune cells and proteins into the brain. Inside the brain, the microglial cells can also produce immune proteins that are involved in the autoimmune process commonly referred to as brain inflammation or neuroinflammation.
Like all typical autoimmune diseases, the autoimmunity to brain has been found through laboratory studies of specialized proteins of the immune system (for example, antibodies and cytokines), autoimmunity testing, and immunotherapy. Immune activation, which is the first step in the onset of autoimmunity, has been shown in patients with multiple sclerosis, autism spectrum disorders, Alzheimer’s disease, Tourette’s syndrome, and obsessive-compulsive disorder. Patients with these diseases also harbor elevated levels of autoantibodies that bind specifically to brain proteins–for example, antibodies to caudate nucleus of the basal ganglia (a brain region involved in Parkinson’s disease) in autism spectrum disorder, Tourette’s syndrome, and obsessive-compulsive disorder; antibodies to amyloid protein-beta in Alzheimer’s disease; and antibodies to myelin basic protein in autism spectrum disorder and multiple sclerosis. Interferon-gamma and interleukin-12, the two proteins of the immune system that initiate autoimmunity, are also activated in patients with brain diseases. Furthermore, many patients also show improvement when administered with immunotherapy using intravenous immunoglobulin, plasmapheresis, transfer factor, and other immune modulating agents.
Clearly, several lines of scientific evidence suggest a pathogenic role of brain autoimmunity or NeuroAutoImmunity in central nervous system diseases. This patient population must be included in all future epidemiological studies if we are going to realize the overall impact of autoimmune diseases. Immunotherapy with immune modulating agents offers a novel promising approach to helping those affected with these medical conditions. Autoimmunity in the brain may also cause a shift in brain waves or states, thereby resulting into a functionally “imbalanced brain.” To that end, a novel approach of Brain State Conditioning (BSC) that stems from brain plasticity (brain’s ability to re-wire and heal itself) might also be quite important in helping people who suffer from brain diseases and mental illnesses involving autoimmunity.
According to the World Health Organization (W.H.O.), the financial burden of all brain diseases and mental illnesses surpasses that of cancer and heart disease. Up to 75-80 percent of patients with brain diseases have autoimmunity, which means that a significant proportion of this population could potentially benefit from interventions directed towards autoimmunity in the brain.
–Further Reading: Annals of Clinical Psychiatry (March, 2009); Neurology 71:265-271 (2008); Tics and Tourette’s (S.J. Rogers, ed.), Chapter 15:163-169 (2005); Neuroscience Letters 355:53-56 (2004); Journal of Biomedical Science 9:359-364 (2002); CMAJ 165:1353-1358 (2001); Gerontology 43:79-94 (1997); Progress in Drug Research 48:129-146 (1997); Molecular & Chemical Neuropathology 28:105-111 (1996).